Perrigo (PRGO) News Today

Perrigo Company plc (PRGO) — Shares moved higher after Q1 results and a stronger-than-expected FY‑2026 earnings guide. Investors are weighing an EPS beat and guidance lift against a sizable revenue miss, margin pressure and ongoing category headwinds.

• Positive Sentiment: Q1 EPS beat consensus—reported $0.43 vs. estimates around $0.39–$0.31, showing better profitability per share than modeled. Perrigo (PRGO) Q1 Earnings Beat EstimatesSource
• Positive Sentiment: Company raised FY‑2026 EPS guidance to $2.25–$2.55, ahead of Street EPS consensus (~$2.11), giving investors a clearer path to improved full‑year earnings. Perrigo Reports First Quarter 2026 Financial ResultsSource
• Positive Sentiment: Specialty Care and brand momentum (Compeed, Opill, ellaOne) and execution of the “Three‑S” plan drove segment growth and market‑share gains, supporting the upbeat guidance tone. Perrigo Results & StrategySource
• Neutral Sentiment: Shareholder meeting outcomes were supportive—directors, executive pay and capital flexibility measures were approved, which reduces proxy uncertainty but is not an earnings catalyst. Perrigo Shareholders Endorse Directors, Pay and Capital FlexibilitySource
• Neutral Sentiment: Management held an earnings call and provided slides/transcript; these should clarify assumptions behind the guide and cost actions (important for modeling but not an immediate swing). Perrigo Q1 2026 Earnings Call TranscriptSource
• Negative Sentiment: Revenue materially missed expectations—$841.8M reported vs. ~ $1.04B consensus—and sales were down ~7.2% YoY, signaling demand/headwind issues despite the EPS beat; net margin remains deeply negative on a continuing‑ops basis. Perrigo Earnings DetailsSource
• Negative Sentiment: Investor concern over portfolio moves (dermacosmetics sale), dividend choices and infant‑formula supply/market strain adds uncertainty around near‑term cash flow and growth. Investors Reacting To Perrigo Dermacosmetics Sale, Dividend Payout, And Infant Formula StrainsSource

Bottom line for investors: the intraday uptick appears driven by the EPS beat and an above‑consensus EPS guide, while revenue weakness, negative margins and portfolio/headline risks remain near‑term downsides. Key catalysts to watch: quarterly revenue trends, margin recovery, and management commentary on the drivers behind the FY guide (from the call/slide deck).